1. Home
  2. WMK vs NRIX Comparison

WMK vs NRIX Comparison

Compare WMK & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weis Markets Inc.

WMK

Weis Markets Inc.

HOLD

Current Price

$66.81

Market Cap

1.6B

ML Signal

HOLD

Logo Nurix Therapeutics Inc. Common stock

NRIX

Nurix Therapeutics Inc. Common stock

HOLD

Current Price

$19.57

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WMK
NRIX
Founded
1912
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
WMK
NRIX
Price
$66.81
$19.57
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
$26.08
AVG Volume (30 Days)
111.9K
1.8M
Earning Date
11-04-2025
01-27-2026
Dividend Yield
2.05%
N/A
EPS Growth
6.99
N/A
EPS
3.81
N/A
Revenue
$4,894,832,000.00
$83,687,000.00
Revenue This Year
N/A
$58.38
Revenue Next Year
N/A
N/A
P/E Ratio
$17.17
N/A
Revenue Growth
2.20
48.32
52 Week Low
$61.53
$8.18
52 Week High
$90.23
$22.95

Technical Indicators

Market Signals
Indicator
WMK
NRIX
Relative Strength Index (RSI) 52.66 70.09
Support Level $64.54 $16.02
Resistance Level $68.00 $22.50
Average True Range (ATR) 1.70 1.33
MACD 0.21 0.32
Stochastic Oscillator 67.89 72.19

Price Performance

Historical Comparison
WMK
NRIX

About WMK Weis Markets Inc.

Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products mainly belong to the following categories: center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: